Efficacy Of First-line CHOP Regimen Treatment On Different Subtypes Of Uygur And Han DLBCL

Objective: To Analyze the efficacy of First-line CHOP regimen treatment ondifferent subtypes of Uygur and Han DLBCL, observe the toxicity. Method:Collect theclinical data of Uygur and Han hospitalized patients been diagnosed DLBCL from2007to2012, all the patients have been treated by6cycles of first-line CHOP regimen.167casesmake the grade. All patients are divided into two group of GCB and non-GCB, assese theefficacy and toxicity of CHOP regimen on different subtypes of Uygur and HanDLBCL.Results:1.there are Han patients including34cases in GCB group (33.0%),non-GCB group of69cases (67.0%), and Uygur patients including22cases (34.4%)in GCB group, and42cases (65.6%) in non-GCB group, It shows no difference in groupproportion(P=0.856).2. GCB group of Uygur patients has22cases, CR+PR17cases,effective rate was77.27%（17/22）,Non-GCB group has42cases, CR+PR14cases,effective rate was33.33%（14/42）,The efficacy of GCB group of Uygur patients is betterthan that of non-GCB group, the difference was statistically significant, P<0.05. it isconsistent with Han’s rusults.3.RR of group GCB of Uygur and Han DLBCL were77.27%and70.59%, no significant difference (P=0.581), RR of group non-GCB of Uygur andHan DLBCL were33.33%and37.68%, these is no statistical significance (P=0.644).4.The main toxicity reactions of the two groups were gastrointestinal reaction, low to middlemyelosuppression and neurotoxicity, the incidence of two groups is near. Conclusions: Itis no difference in the proportion of immune patten of DLBCL in Han and Uygur, Both inthe non-GCB group patients for more; Efficacy of GCB subtype of Uygur DLBCL isbetter than that of non-GCB subtype,Immune subtype is pretictive for efficacy of UygurDLBCL too; Uygur and Han patients can tolerate the toxicity of CHOP regimen.